|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NEAT1-TFE3 RCC arose in a 59-year-old male; which demonstrated overlapping morphological features seen in NEAT2(MALAT1)-TFEB t(6;11) renal cell carcinoma, including biphasic alveolar/nested tumor cells with eosinophilic cytoplasm.
|
30622287 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, LncRNA MALAT1/miR-194-5p/ACVR2B signaling was regarded as a candidate pathway for modulating KIRC progression.
|
30334578 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study demonstrated that MALAT1 functions as a miR-203 decoy to increase BIRC5 expression in RCC.
|
31250518 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MALAT1 was highly expressed and the expression of miR‑22‑3p was suppressed in RCC tissues and cell lines.
|
30431104 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two transcription factors in this family have been identified in two unusual types of renal cell carcinoma (RCC): Xp11 translocation RCC harbouring TFE3 gene fusions and t(6;11) RCC harbouring a MALAT1-TFEB gene fusion.
|
29148086 |
2018 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LncRNA MALAT-1 and the Livin protein were highly expressed in RCC tissues, as well as in RCC 786-O and Caki-1 cell lines.
|
27655020 |
2017 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A subset of renal cell carcinomas shows TFEB overexpression secondary to MALAT1-TFEB gene fusion.
|
28338654 |
2017 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high expression of MALAT1 could be considered a biomarker of the early detection of lymph node metastasis and predictor of poor survival in RCC patients, who likely manifested short overall survival (OS; hazard ratio [HR], 2.97; 95% CI, 1.68-5.28; p<0.001).
|
27527868 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results imply that MALAT-1 can be used to predict unfavorable prognoses for several cancers, particularly RCC.
|
26909935 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of MALAT1 expression may be a promising strategy for KIRC therapy.
|
26461224 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, our findings illuminate how overexpression of MALAT1 confers an oncogenic function in RCC that may offer a novel theranostic marker in this disease.
|
25600645 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of five TFE3 gene fusions (PRCC-TFE3, ASPSCR1-TFE3, SFPQ-TFE3, NONO-TFE3, and CLTC-TFE3) and one TFEB gene fusion (MALAT1-TFEB) have been identified in RCC tumours and characterized at the mRNA transcript level.
|
25048860 |
2014 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A subset of renal cell carcinomas (RCCs) is characterized by t(6;11)(p21;q12), which results in fusion of the untranslated Alpha (MALAT1) gene to the TFEB gene.
|
22892601 |
2012 |